AI has revolutionised the way drugs are discovered.We use AI to discover new indications for existing drugs, derisking clinical development and reducing the cost and time needed to bring an effective drug to market.
Our drug repurposing activities focus on orphan diseases with high unmet medical needs, high potential market values and high regulatory and IP protection. Drug repurposing significantly lowers drug development costs, decreases development time and represents a growing market, currently estimated at USD 317 billion..
Most orphan diseases are life threatening, therefore there is an urgent need to find new treatments. The global orphan disease market has been growing strongly at 10%+ CAGR and is expected to reach USD 242 billion in 2024.